American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

Event · Earnings
Also in this documentGuidance · raise · $204M–$206M

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 3, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AMWL
Bearish
high confidence
Mentioned
$AMWL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AMWLBearishHigh
01

Why it matters

The company issued guidance raising its 2026 revenue outlook and reaffirming AMG visit targets while reporting a widening loss, which may prompt short‑term selling.

02

Market read

First‑report earnings with new guidance and loss figures create immediate trading relevance for AMWL and related telehealth stocks.

03

What to watch

Positive cash‑flow outlook for Q4 and expanding AI‑driven care platform may support longer‑term upside.

Relevance 7/10Novelty 8/10Timing: after‑hours today
AlphAI · Earnings readAMWL · third quarter 2026 · ended September 30, 2026

Amwell reported Total Revenue of $49.0 million, exceeding its previously provided Q3 financial guidance range, while raising its 2026 revenue and adjusted EBITDA outlook.

→Mixed quarter

Q3 revenue exceeded the company’s previously provided guidance range and Amwell raised its full-year revenue and adjusted EBITDA outlook, but revenue was below the prior-year quarter, GAAP net loss and adjusted EBITDA worsened sequentially, and the company remained loss-making.

Revenue
$49.0M
Subscription revenue
$23.9M
Gross margin · GAAP
53%
EPS · GAAP
$ (0.67 )
2026 and Q4 2026 outlook
2026: $204 million to $206 million; Q4 2026: $48 million to $50 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenue, Three Months Ended September 30, 2026GAAP$48.99M––
Costs of revenue, excluding depreciation and amortization of intangible assets, Three Months Ended September 30, 2026GAAP23,032––
Gross margin, third quarter 2026GAAP53%––
Research and development, Three Months Ended September 30, 2026GAAP9,595––
Sales and marketing, Three Months Ended September 30, 2026GAAP7,285––
General and administrative, Three Months Ended September 30, 2026GAAP15,493––
Depreciation and amortization expense, Three Months Ended September 30, 2026GAAP5,240––
Total costs and operating expenses, Three Months Ended September 30, 2026GAAP60,645––
Loss from operations, Three Months Ended September 30, 2026GAAP(11,654 )––
Interest income and other (expense) income, net, Three Months Ended September 30, 2026GAAP1,465––
Income tax expense, Three Months Ended September 30, 2026GAAP(769 )––
Net loss, Three Months Ended September 30, 2026GAAP−$10.96M––
Net loss attributable to American Well Corporation, Three Months Ended September 30, 2026GAAP−$11.36M––
Net loss per share attributable to common stockholders, basic and diluted, Three Months Ended September 30, 2026GAAP$ (0.67 )––
Adjusted EBITDA, Three Months Ended September 30, 2026non-GAAP−$3.60M––
Total visits on the platform, third quarter 2026other800K––
Revenue, Nine Months Ended September 30, 2026GAAP$155.9M––
Loss from operations, Nine Months Ended September 30, 2026GAAP(38,634 )––
Net gain on divestiture, Nine Months Ended September 30, 2026GAAP7,027––
Net loss, Nine Months Ended September 30, 2026GAAP−$30.88M––
Net loss attributable to American Well Corporation, Nine Months Ended September 30, 2026GAAP−$32.17M––
Net loss per share attributable to common stockholders, basic and diluted, Nine Months Ended September 30, 2026GAAP$ (1.91 )––
Adjusted EBITDA, Nine Months Ended September 30, 2026non-GAAP−$7.83M––
Net cash used in operating activities, Nine Months Ended September 30, 2026GAAP(1,934 )––
Net cash (used in) provided by investing activities, Nine Months Ended September 30, 2026GAAP(1,590 )––
Net cash provided by financing activities, Nine Months Ended September 30, 2026GAAP541––
Cash and cash equivalents, September 30, 2026GAAP$180.8M––
Total assets, September 30, 2026GAAP$309.2M––
Total liabilities, September 30, 2026GAAP84,050––
Total stockholders’ equity, September 30, 2026GAAP225,166––

Segments

SegmentRevenueq/qy/y
Subscription revenueSubscription revenue was reported as a component of third-quarter total revenue.$23.9M––
Amwell Medical Group (“AMG”) visit revenueAMG visit revenue was reported as a component of third-quarter total revenue.$23.7M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2026 and Q4 2026 outlook

  • Revenue2026: $204 million to $206 million; Q4 2026: $48 million to $50 million
  • Note2026 AMG visits: between 1.32 million and 1.37 million
  • Note2026 Adjusted EBITDA: between ($8) million to ($7) million
  • NoteQ4 2026 Adjusted EBITDA: $0 million to $1 million
  • NoteObjective to achieve positive cash flow from operations in the fourth quarter of 2026

Capital returns

  • Payments for the purchase of treasury stock: (1 ) for the Nine Months Ended September 30, 2026.
  • Proceeds from employee stock purchase plan: 542 for the Nine Months Ended September 30, 2026.

What drove it

  • The company reported subscription revenue of $23.9 million and AMG visit revenue of $23.7 million.
  • Total visits on the platform were 0.8 million.
  • Management described six focus areas running on one platform and cited activation of more members, simplified member experience, deeper clinician relationships, customer choice, demonstrated outcomes, and a common data structure.
  • The adjusted EBITDA reconciliation included depreciation and amortization, interest income and other income (expense), income tax expense, stock-based compensation, severance and strategic transformation costs, and a gain on divestiture related to the sale of the APC business.

Concerns

  • Third-quarter revenue was $ 48,991 compared with $ 56,286 in the prior-year quarter.
  • Third-quarter net loss was $ (10,958 ) compared with $ (9,625) in the second quarter of 2026.
  • Third-quarter adjusted EBITDA was $ (3,598) compared with $ (1,150) in the second quarter of 2026.
  • Management identified risks including client-platform transition and attrition, renewal and upsell execution, continuation of the Defense Health Agency relationship beyond Q3 2026 with comparable financial terms, telehealth-market volatility, technological change, competition, regulation, privacy compliance, cybersecurity, and transformation execution.

What to watch

  • Q4 2026 revenue guidance of $48 million to $50 million.
  • Q4 2026 Adjusted EBITDA guidance of $0 million to $1 million.
  • The reiterated objective to achieve positive cash flow from operations in the fourth quarter of 2026.
  • Execution against 2026 AMG visit guidance of between 1.32 million and 1.37 million.
  • Continuation of the Defense Health Agency relationship beyond Q3 2026 with comparable financial terms.

Balance sheet and cash flow

  • Cash and cash equivalents: $ 180,786 as of September 30, 2026.
  • Restricted cash: 795 as of September 30, 2026.
  • Total cash, cash equivalents, and restricted cash: $ 181,581 at the end of the Nine Months Ended September 30, 2026.
  • Net cash used in operating activities: (1,934 ) for the Nine Months Ended September 30, 2026.
  • Capitalized software development costs: (8,594 ) for the Nine Months Ended September 30, 2026.
  • Purchases of property and equipment: (23 ) for the Nine Months Ended September 30, 2026.
  • Proceeds from divestiture, net of cash divested: 7,027 for the Nine Months Ended September 30, 2026.
  • No debt balance was reported in the provided balance sheet.

Analysis

Amwell reported third-quarter GAAP revenue of $ 48,991, versus $ 56,286 in the prior-year quarter. The company said its $49.0 million of Total Revenue exceeded the previously provided Q3 financial guidance range. Subscription revenue was $23.9 million and AMG visit revenue was $23.7 million, while total platform visits were 0.8 million. Gross margin was 53%.

The income statement showed substantial year-over-year reductions in operating expense line items. Research and development was 9,595 versus 18,582, sales and marketing was 7,285 versus 9,078, general and administrative expense was 15,493 versus 21,736, and depreciation and amortization expense was 5,240 versus 9,443. Total costs and operating expenses were 60,645 compared with 85,618. Loss from operations was (11,654 ) and net loss was $ (10,958 ), compared with $ (31,911 ) in the prior-year period.

Sequential profitability moved adversely. Net loss was $ (10,958 ) compared with $ (9,625) in the second quarter of 2026, and adjusted EBITDA was $ (3,598) compared with $ (1,150). The nine-month adjusted EBITDA loss was $ (7,828), compared with $ (29,581) for the comparable 2025 period. The company’s reconciliation identifies severance and strategic transformation costs as expenses associated with employee terminations and costs related to transforming its sales and growth organization and overall cost structure.

Liquidity remained substantial in the reported balance sheet, with cash and cash equivalents of $ 180,786 and total cash, cash equivalents, and restricted cash of $ 181,581 at September 30, 2026. Net cash used in operating activities for the nine months was (1,934 ), compared with (48,598 ) a year earlier. Investing cash flow included (8,594 ) of capitalized software development costs and 7,027 of proceeds from divestiture, net of cash divested.

Management raised 2026 revenue guidance to $204 million to $206 million from $200 million to $205 million and raised adjusted EBITDA guidance to between ($8) million to ($7) million from between ($9) million to ($7) million. It reaffirmed AMG visit guidance of between 1.32 million and 1.37 million. For Q4, Amwell guided revenue to $48 million to $50 million and adjusted EBITDA to $0 million to $1 million, alongside its reiterated objective of positive cash flow from operations in the fourth quarter of 2026.

Management, verbatim

Health plans and employers want engagement, outcomes and proof, and Amwell’s single platform is built to deliver all three.

Dr. Ido Schoenberg, Chairman and CEO of Amwell

We expect to generate positive cash flow from operations in the fourth quarter, and we believe we are well positioned to be the trusted platform where AI-powered care runs.

Dr. Ido Schoenberg, Chairman and CEO of Amwell

Not in the filing

stated, not guessed
  • Previous-release outlook was not provided, so no formal comparison of Q3 actual results with prior guidance is available.
  • Q3 2026 free cash flow was not reported.
  • Q3 2026 operating cash flow was not reported. Operating cash flow was reported only for the nine months ended September 30, 2026.
  • Debt was not reported in the provided balance sheet.
  • Non-GAAP EPS was not reported.
  • Gross-margin prior-year and prior-quarter comparisons were not reported.
  • Subscription revenue and AMG visit revenue prior-year and prior-quarter comparisons were not reported.
  • Q4 and full-year 2026 gross margin, operating expense, and tax-rate guidance were not reported.
  • No dividend or share-repurchase program announcement was reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Amwell (NYSE: AMWL) is a SaaS‑based telehealth platform that filed its Q3 2026 earnings via an SEC Form 8‑K.

Company-level read

Ticker impact

$AMWLBearishHigh confidence
Context

Amwell reported Q3 2026 results with revenue $49M, net loss $11M and raised its 2026 revenue outlook to $204M-$206M.

Expected impact

likely pressure as the market prices in the reported loss and modest outlook

Evidence & confidence

First‑report 8‑K earnings with new numbers; loss exceeds prior quarter and guidance, prompting traders to reassess valuation.

Market effects

Telehealth sector may see heightened scrutiny on profitability as Amwell signals continued losses.

U.S. healthcare technology stocks could experience modest downside pressure.

Limited to U.S. listed telehealth players.

Counterpoint

If investors focus on top‑line growth and AI‑enabled platform potential, the stock could rebound despite the loss.

Key entities

  • Ido Schoenberg

    Chairman and CEO of Amwell who provided the earnings commentary.

Every AMWL earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.

$AMWLMed

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE Second QUARTER 2026 BOSTON, August 4 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30, 2026